The Science Behind the Drug That May Stop Alzheimer’s Disease in Its Tracks

3 min video | 1 min read

A First of Its Kind, ALZ-801 Aims To Preserve Memories, Save Lives: An Exclusive Interview with Dr. Martin Tolar

8 min video | 1 min read

Unprecedented Reduction in Key Alzheimer’s Biomarker for Patients Treated With ALZ-801

6 min video | 1 min read

Part 1: The Role of APOE Genotyping in Alzheimer’s Disease Risk Stratification

8 min video

Part 2: APOE Genotyping in Clinical Practice: Pros and Cons

8 min video

Learn More About Advances in AD Treatments

3 min read

Unprecedented Reduction in Key Alzheimer’s Biomarker for Patients Treated With ALZ-801

by John Hey, PhD
Chief Scientific Officer, Alzheon, Inc.

A correlation between reduction in plasma p-tau181 and improvement of memory and function has been shown with leading antibodies in patients with Alzheimer’s disease. Alzheon’s ALZ-801 (valiltramiprosate) has resulted in a significant 41% reduction in plasma p-tau at 12 months. This is greater than reductions observed with leading antibodies at 18 months. Watch now to find out what this could mean for patients with Alzheimer’s disease.